Collectively, this study supports the hypothesis that menin silencing can trigger apoptosis and inhibit tumor growth in TNBC and provides a rationale for the use of ASO-based therapeutics against menin as a monotherapy or in combination with chemo or PARP inhibitors in menin-positive TNBC. This evidence concerns the gene PARP1 and neoplasm.